INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“LENZ” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LENZ and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around December 12, 2025, a case of retinal tear associated with LENZ’s VIZZ eye drop appeared in the Food and Drug Administration’s adverse event reporting systems. As media outlets and analysts reported on the appearance, LENZ’s stock price fell $6.36 per share, or 25.96%, to close at $18.14 per share on December 12, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corpora
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZPR Newswire
- LENZ Therapeutics: Was That A Market Overreaction? [Seeking Alpha]Seeking Alpha
- LENZ Therapeutics (NASDAQ:LENZ) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of PresbyopiaGlobeNewswire
- LENZ Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
LENZ
Earnings
- 11/5/25 - Beat
LENZ
Sec Filings
- 12/12/25 - Form 8-K
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- LENZ's page on the SEC website